GENinCode PLC
GENI
Company Profile
Business description
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.
Contact
Oxford Science Park
John Eccles House, Robert Robertson Avenue
OxfordOX4 4GP
GBRT: +44 1865676125
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,093.80 | 34.30 | 0.38% |
| CAC 40 | 8,384.01 | 33.14 | 0.40% |
| DAX 40 | 24,894.01 | 258.71 | 1.05% |
| Dow JONES (US) | 51,671.03 | 468.77 | 0.92% |
| FTSE 100 | 10,430.62 | 41.10 | -0.39% |
| HKSE | 24,589.86 | 252.81 | -1.02% |
| NASDAQ | 26,683.94 | 795.10 | 3.07% |
| Nikkei 225 | 69,148.60 | 168.90 | -0.24% |
| NZX 50 Index | 13,386.65 | 26.06 | 0.20% |
| S&P 500 | 7,554.29 | 122.83 | 1.65% |
| S&P/ASX 200 | 8,879.60 | 39.20 | 0.44% |
| SSE Composite Index | 4,087.36 | 9.11 | -0.22% |